Foscarnet sodium

Area of Science:

• Virology
• Immunology
• Ophthalmology

Background:

• Cytomegalovirus (CMV) is an opportunistic pathogen causing severe disease in immunocompromised individuals, particularly CMV retinitis in AIDS patients.
• Ganciclovir is the primary treatment for CMV retinitis but often causes dose-limiting myelosuppression, especially when combined with other AIDS medications.
• Alternative treatments are needed for CMV retinitis, considering the limitations of current therapies.

Purpose of the Study:

• To evaluate foscarnet sodium as an alternative treatment for cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).
• To compare the efficacy and toxicity profile of foscarnet with ganciclovir for CMV retinitis management.

Main Methods:

• Intravenous foscarnet therapy was administered to patients with CMV retinitis.
• Initial daily doses ranged from 180-230 mg/kg/d in divided infusions, followed by maintenance regimens of 60-90 mg/kg/d as single daily infusions.
• Patient outcomes, including viral load suppression and adverse events, were monitored.

Main Results:

• Foscarnet demonstrated favorable results in treating CMV retinitis.
• A significant advantage of foscarnet is its lack of major myelosuppressive toxicity compared to ganciclovir.
• Foscarnet also exhibited activity in suppressing human immunodeficiency virus type 1 (HIV-1) replication.

Conclusions:

• Foscarnet sodium is a potentially safe and effective alternative agent for managing CMV infection, particularly CMV retinitis in AIDS patients.
• Its efficacy against CMV and HIV, coupled with minimal myelosuppression, makes it a valuable option when ganciclovir is contraindicated or poorly tolerated.
• Potential renal impairment necessitates careful monitoring during foscarnet therapy, and long-term treatment may be required to prevent relapse.